Da Yu Protein Sciences – News
FOR IMMEDIATE RELEASE
Date: December 19, 2012
DA YU ENTERPRISES RECEIVES A GRANT FROM THE NATIONAL SCIENCE FOUNDATION FOR RECOMBINANT PROTEIN SYNTHESIS TECHNOLOGY DEVELOPMENT
NSF grant will further development of in vitro protein synthesis technology for properly-folded proteins.
Doylestown, Pennsylvania – (Biotech News Release) - Da Yu Enterprises, LLC, announced today the receipt of a Phase I Small Business Innovation Research (SBIR) Grant from the National Science Foundation. The grant, titled “Production of Properly-Folded Recombinant Proteins in Escherichia coli”, will enable Da Yu Protein Sciences, a wholly-owned subsidiary of Da Yu Enterprises, LLC, to demonstrate proof of concept for its innovative and proprietary in vitro protein synthesis technology to produce recombinant proteins with their native structure.
“We are honored to receive this prestigious grant from the National Science Foundation”, commented Donald O’Keefe, Ph.D., M.B.A., Managing Director of Da Yu Protein Sciences. “With only approximately 220 NSF SBIR Phase I grants awarded in 2012, Da Yu Enterprises is among a select group of companies recognized by the NSF for cutting-edge, high risk, and high quality scientific research” stated Dr. O’Keefe.
Da Yu Protein Sciences is pioneering a new gene expression platform that combines the advantages of E. coli-based recombinant protein production with those of in vitro protein synthesis. This innovative technology is aimed at addressing many unmet needs in drug discovery, Biologics development and Biologics manufacturing that require properly-folded recombinant proteins. Da Yu Protein Sciences is pursuing specific applications for this technology in the areas of functional and structural genomics, pharmaceutical drug discovery, and Biologics development and manufacturing.
About Da Yu Enterprises, LLC
Da Yu Enterprises, LLC, is a privately-held, technology-based company focused on the development of innovative products and services for its clients. The Company’s client base includes nonprofit and for-profit biomedical research and development organizations pursuing Biologics development or drug discovery. For more information, please visit www.dayuenterprises.com.